Neuroimmune Pharmacology and Therapeutics
暫譯: 神經免疫藥理學與治療學

Dr. Howard E. Gendelman is the Margaret R. Larson Professor of Internal Medicine and Infectious Diseases, Chairman of the Department of Pharmacology and Experimental Neuroscience, and Director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center. Dr. Gendelman is credited in unraveling the functional immune alterations in brain and how they induce metabolic changes and lead to neural cell damage in a range of chronic infectious and neurodegenerative disorders. The discoveries led to immune transformative therapeutics aimed at preventing, slowing, or reversing neural maladies currently in clinical trials. He is also credited for the demonstration that AIDS dementia is a reversible metabolic encephalopathy. His work has led to regulatory T cell-based immunotherapies for Parkinson's and more recently Alzheimer's disease are being tested in early clinical trials as a result of intense translational investigations. He is a co-founder of Exavir Therapeutics, Inc., a biotechnology start-up focused on developing ultra-long acting therapies for chronic diseases. Dr. Gendelman obtained a Bachelor's degree in Natural Sciences and Russian Studies with honors from Muhlenberg College and his MD from the Pennsylvania State University-Hershey Medical Center where he was the 1999 Distinguished Alumnus. He completed a residency in Internal medicine at Montefiore Hospital, Albert Einstein College of Medicine and was a Clinical and Research Fellow in Neurology and Infectious Diseases at the Johns Hopkins University Medical Center. He occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the National Institute of Allergy and Infectious Diseases, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry Jackson Foundation for the Advancement in Military Medicine before joining the University of Nebraska Medical Center faculty in March of 1993. He retired from the US Army with the rank of Lieutenant Colonel. Dr. Gendelman has authored over 580 peer-reviewed publications, edited 12 books and monographs, holds 112 patents, is the Editor-In-Chief and Founder of the Journal of Neuroimmune Pharmacology from 2004-2021 and currently NeuroImmune Pharmacology and Therapy along with service on numerous editorial boards, national and international scientific review and federal and state committees. He has been an invited lecturer to more than 300 scientific seminars and symposia and the recipient of numerous local, national, and international honors. He is a true luminary of the medical center as the recipient of the the University of Nebraska's IP Innovation and Commercialization Award based on his development of significant new intellectual property from concept to licensing/startup business. Dr. Gendelman has patented more than 200 new inventions and is moving to or already has begun several Phase I-II studies. In addition, he received the Henry L. Moses Award in Basic Science; the Carter-Wallace Fellow for Distinction in AIDS Research, the David T. Purtilo Distinguished Chair of Pathology and Microbiology; the Margaret R. Larson Professor of Infectious Diseases and Internal Medicine; being named a Nebraska Pioneer; a UNMC Scientist Laureate; a NU Outstanding Research and Creativity Award winner, the 2013 UNMC Innovator of the Year, the 2014 Outstanding Faculty Mentor of Graduate Students; the Life Saver Award from the Nebraska Coalition for Lifesaving Cures, the Intellectual Property, Innovation and Commercialization Award; and the Pioneer in Neurovirology Award by the International Society for NeuroVirology. He is also the President of the Society on NeuroImmune Pharmacology and the recipient of the humanitarian award given by the Jewish Federation of Omaha. The society granted him the Joseph Wybran, Herman Friedman, and Lifetime Service Awards. Dr. Gendelman was also named a J. William Fulbright Research Scholar at the Weizmann Institute of Science in Israel. He received the prestigious Jacob Javits Neuroscience Research Award from the National Institute of Neurological Disorders and Stroke and the Career Research Award in Medicine from the Department of Internal Medicine, UNMC. He enjoys a current Hirsch Index of 119 as listed on highly cited.com as one of the top-cited scientists in his field.

Dr. Tsuneya Ikezu is a Professor in the Department of Neuroscience and Director of Molecular Neurotherapeutics Laboratory at the Mayo Clinic in Florida. After receiving his M.D. and Ph.D. at the University of Tokyo School of Medicine. Dr. Ikezu is best known for his groundbreaking work deciphering the role of extracellular vesicles (EVs) secreted from microglia on the progression of Alzheimer's disease (AD). Dr. Ikezu characterized the protein composition of EVs isolated from the brain tissues, cerebrospinal fluid, or plasma of AD patients and related disorders, and discovered pathological function of EVs and their potential as cell type-specific biomarkers for neurodegenerative diseases. Prior to this, Dr. Ikezu was Professor of Pharmacology and Neurology at Boston University School of Medicine until 2020. He has authored more than 139 journal articles, which were cited over 23,000 times and served on several editorial boards including the Journal of Extracellular Vesicles. Dr. Ikezu has received numerous awards including Inge Grundke-Iqbal Award from Alzheimer's Association (2016), Jack Spivack Excellence in Neuroscience Award from Boston University School of Medicine (2018), and Investigator of the Year Award from Mayo Clinic Florida (2023). Dr. Ikezu's educational background includes a medical degree from the Faculty of Medicine, University of Tokyo; a Ph.D. from the University of Tokyo Graduate School of Medicine.

霍華德·E·根德曼博士是內科及傳染病的瑪格麗特·R·拉爾森教授，內科藥理學與實驗神經科學系主任，以及內布拉斯加醫學中心神經退行性疾病中心的主任。根德曼博士在揭示大腦功能性免疫變化及其如何引發代謝變化並導致各種慢性傳染病和神經退行性疾病中的神經細胞損傷方面，獲得了廣泛的認可。這些發現促成了針對預防、減緩或逆轉神經疾病的免疫轉化療法，目前正在臨床試驗中。他還被認為證明了艾滋病癡呆是一種可逆的代謝性腦病。他的研究導致基於調節性T細胞的免疫療法，針對帕金森病和最近的阿茲海默病，這些療法正在早期臨床試驗中進行測試，這是由於強烈的轉化研究。他是Exavir Therapeutics, Inc.的共同創辦人，這是一家專注於開發超長效慢性病療法的生物技術初創公司。根德曼博士在穆倫堡學院獲得自然科學和俄語研究的榮譽學士學位，並在賓夕法尼亞州立大學-赫爾希醫學中心獲得醫學博士學位，並於1999年被評為傑出校友。他在蒙特菲奧爾醫院、阿爾伯特·愛因斯坦醫學院完成內科住院醫師訓練，並在約翰·霍普金斯大學醫學中心擔任神經學和傳染病的臨床及研究研究員。他曾在約翰·霍普金斯醫學機構、國家過敏與傳染病研究所、統一服務健康科學大學、沃爾特·里德陸軍研究所和亨利·傑克遜軍醫進步基金會擔任高級教職和研究職位，並於1993年3月加入內布拉斯加醫學中心的教職。他以中校的軍階從美國陸軍退役。根德曼博士已發表超過580篇經過同行評審的出版物，編輯了12本書籍和專著，擁有112項專利，並於2004年至2021年擔任《神經免疫藥理學期刊》的主編和創始人，目前擔任《神經免疫藥理學與療法》的主編，並在多個編輯委員會、國內外科學評審及聯邦和州委員會中服務。他曾受邀在300多個科學研討會和座談會上演講，並獲得多項地方、國家和國際榮譽。他是內布拉斯加醫學中心的真正燦爛之星，因其從概念到授權/創業的重大新知識產權的開發而獲得內布拉斯加州的IP創新與商業化獎。根德曼博士已獲得超過200項新發明的專利，並正在進行或已開始幾個I-II期研究。此外，他還獲得亨利·L·摩西基礎科學獎；艾滋病研究卓越的卡特-華萊士獎學金，病理學和微生物學的戴維·T·普提洛傑出講座；傳染病和內科的瑪格麗特·R·拉爾森教授；被評為內布拉斯加州的先驅；UNMC科學家榮譽獎；NU傑出研究與創意獎得主，2013年UNMC年度創新者，2014年研究生傑出導師；內布拉斯加州生命拯救療法聯盟的生命拯救獎，知識產權、創新與商業化獎；以及國際神經病毒學會的神經病毒學先驅獎。他還是神經免疫藥理學會的會長，並獲得奧馬哈猶太聯合會頒發的人道主義獎。該學會授予他約瑟夫·維布蘭、赫爾曼·弗里德曼和終身服務獎。根德曼博士還被評為以色列魏茨曼科學研究所的J·威廉·富布賴特研究學者。他獲得國家神經疾病與中風研究所的雅各布·雅維茨神經科學研究獎和UNMC內科部的職業研究獎。他目前的Hirsch指數為119，並在highly cited.com上被列為其領域中被引用最多的科學家之一。

池根彌博士是佛羅里達州梅奧診所神經科學系的教授及分子神經治療實驗室的主任。在東京大學醫學院獲得醫學博士和博士學位後，池博士以其在解碼微膠質細胞分泌的細胞外囊泡（EVs）在阿茲海默病（AD）進展中的作用方面的開創性工作而聞名。池博士對從AD患者及相關疾病的腦組織、腦脊髓液或血漿中分離的EVs的蛋白質組成進行了特徵分析，並發現了EVs的病理功能及其作為神經退行性疾病的細胞類型特異性生物標記的潛力。在此之前，池博士曾在波士頓大學醫學院擔任藥理學和神經學教授，直到2020年。他已發表超過139篇期刊文章，這些文章被引用超過23,000次，並在包括《細胞外囊泡期刊》在內的多個編輯委員會中任職。池博士獲得了多項獎項，包括2016年艾滋病協會的英格·格倫德克-伊克巴爾獎、2018年波士頓大學醫學院的傑克·斯皮瓦克神經科學卓越獎，以及2023年梅奧診所佛羅里達州的年度研究員獎。池博士的教育背景包括東京大學醫學院的醫學學位；東京大學醫學研究生院的博士學位。